Innovative research initiatives in the field of tissue regeneration, including pioneering discoveries by University of Vermont Professor of Medicine Daniel Weiss, M.D., Ph.D., and colleagues, holds promise for this population, which includes an estimated 12.7 million people with chronic obstructive pulmonary disorder , the third leading cause of death in the U.S. Previously year alone, Weiss and colleagues published four articles in Biomaterials, the leading bioengineering journal, and also two March 2014 content by first writer Darcy Wagner, Ph.D., a postdoctoral fellow working in Weiss' lab, reporting their development of new strategies and approaches for engineering lungs for individuals with COPD and pulmonary fibrosis.All analyses were conducted by using SAS software, version 9.3 . Results Research Population All PCI centers in Sweden and Iceland , along with 1 PCI middle in Denmark, participated in the trial. Through the study period, 11,956 patients underwent PCI for STEMI, and 7244 were enrolled . During 24 months and 9 weeks of enrollment, 59.7 percent of all the patients presenting with STEMI and known for PCI, and 76.9 percent of all the patients potentially eligible for enrollment in Sweden and Iceland, underwent randomization.